Published in Medical Device Law Weekly, February 4th, 2007
It also received CE mark approval during this same time period.
"My experience with SurgiFrost XL in a preclinical setting confirms its ability to create durable, transmural lesions in a beating heart," said Dr. Saqib Masroor from Hackensack University Medical Center in Hackensack, New Jersey. "Given these results,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.